Is Phlogenzym Effective in Reducing Moderate to Severe Osteoarthritis Pain in Adults? by Wood, Vanessa K.
Philadelphia College of Osteopathic Medicine
DigitalCommons@PCOM
PCOM Physician Assistant Studies Student
Scholarship Student Dissertations, Theses and Papers
2013
Is Phlogenzym Effective in Reducing Moderate to
Severe Osteoarthritis Pain in Adults?
Vanessa K. Wood
Philadelphia College of Osteopathic Medicine, vanessawo@pcom.edu
Follow this and additional works at: http://digitalcommons.pcom.edu/pa_systematic_reviews
Part of the Medical Pharmacology Commons, Musculoskeletal Diseases Commons, and the
Orthopedics Commons
This Selective Evidence-Based Medicine Review is brought to you for free and open access by the Student Dissertations, Theses and Papers at
DigitalCommons@PCOM. It has been accepted for inclusion in PCOM Physician Assistant Studies Student Scholarship by an authorized
administrator of DigitalCommons@PCOM. For more information, please contact library@pcom.edu.
Recommended Citation
Wood, Vanessa K., "Is Phlogenzym Effective in Reducing Moderate to Severe Osteoarthritis Pain in Adults?" (2013). PCOM Physician
Assistant Studies Student Scholarship. Paper 139.
 
 
 
 
Is Phlogenzym effective in reducing moderate to severe 
osteoarthritis pain in adults? 
 
 
Vanessa K. Wood, PA-S 
A SELECTIVE EVIDENCE BASED MEDICINE REVIEW 
In Partial Fulfillment of the Requirements for  
The Degree of Master of Science 
In 
Health Sciences-Physician Assistant 
 
Department of Physician Assistant Studies  
Philadelphia College of Osteopathic Medicine  
Philadelphia, Pennsylvania 
 
 
December 14, 2012 
 
 
 
 
 
 
Abstract 
Objective:  The objective of this selective EBM review is to determine whether or not 
Phlogenzym (or ERC) effective in reducing moderate to severe osteoarthritis pain in adults. 
 
Study Design:  Review of three randomized controlled trials in the English language from 2001 
to 2006. 
 
Data Sources: Two double blind RCTs and one open RCT was found using Cochrane Library 
EBM Online Database, Ovid Medline, and PubMed Online. 
 
Outcomes Measured: Each of the three studies measured for pain at rest, pain with motion, and 
restricted function at baseline assessing efficacy using the Lequesne’s Algofunctional Index, 
visual analog scales, and global judgment. The participants were assessed at baseline, during, 
and at the end of the study.  
 
Results: Two double blind RCTs and one open RCT were included in this review and it was 
found that phlogenzym did not benefit osteoarthritis symptom improvement. Adverse events 
were reported in the two double blind RCTs. 
 
Conclusions:  The results of the three studies reviewed demonstrated that phlogenzym does have 
association with minimal osteoarthritis symptom reduction, but does not provide adequate 
statistical difference between the intervention and control. 
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INTRODUCTION 
Osteoarthritis (OA) is a chronic and progressive disease, and is the most common form of 
arthritis affecting both men and women. OA is known as the “wear-and-tear arthritis” due to the 
degeneration of cartilage and underlying bone.1 This disease affects over 26 million adults and is 
a major cause of morbidity and mortality for adults aged 55 years and older.1 Primary OA is 
idiopathic and is associated with aging; while secondary OA is associated with trauma, 
congenital, metabolic, endocrine, neuropathic, and other medical conditions1. This condition has 
a large impact on a person’s overall health and quality of life. 
Currently there is no cure available for OA and despite research and education efforts, the 
Center of Disease Control and Prevention (CDC) reports an overall prevalence of 13.9% for 
adults over the age of 25 years, and 33.6% for age 65 years and older. The health care cost of OA 
is estimated at $7.9 billion for knee and hip replacements, with the annual disease cost equaling 
$5,700 and an average of $2,600 per year out-of-pocket expense for individuals1. In 1997, 
patients with a primary diagnosis of osteoarthritis accounted for 7.1 million ambulatory care 
visits1. These numbers are thought to be vastly underestimated due to approximately 39% of 
people’s inability to access needed healthcare1.  
Patients seek treatment from physician assistants and health care providers on a daily 
basis for pain relief and improvement of quality of life and function. There are few medications 
that can be prescribed and many are associated with multiple side effects, which have stimulated 
a market for alternative approaches for joint pain improvement and relief. No cure is currently 
available for osteoarthritis. Typically a combination of patient education, physical therapy, 
weight control, medications, and surgery are used to relieve symptoms, minimize disability, and 
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improve function.1,2 Phlogenzym may offer a safe alternative to medications and surgery in 
combination with therapy and weight loss to relieve OA symptoms and improve function.  
The specific causes of osteoarthritis is unknown, but is thought to be due to mechanical 
and molecular events that damage the joint. These events lead to a progressive and gradual onset 
of changes that result in degeneration of the hyaline cartilage and bone within a joint.1,2 
Symptoms are characterized by joint pain, swelling, and stiffness with radiographic changes. 1,2 
The joints that are commonly affected are the knees, hips, hands, and spine. Klein et al. describes 
the chronic disease as a “degenerative, non-systemic joint disease with clinical manifestation of 
pain, stiffness, and limitation of movement due to cartilage loss and local inflammation” that 
primarily affects people older than 55 years and the incidence increases with age.  
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not Phlogenzym 
(or ERC) is effective in reducing moderate to severe osteoarthritis pain in adults. 
METHODS 
 A detailed search was performed by the author of this review between December 2011 
and January 2012 using the Cochrane Library EBM Online Database and PubMed Online, with 
the key words “phlogenzym”, “bromelain”, osteoarthritis”, and “knee pain”. All three articles 
selected in this review were published in English and in peer-reviewed journals between 2001 
and 2006. Only studies that reported patient-oriented outcomes were accepted by the author and 
also the relevance of the topic of interest. The population was limited to patients greater than 18 
years of age with symptomatic osteoarthritis. Only blinded, randomized, controlled trials that 
compared phlogenzym and diclofenac were considered. Outcomes of interest included efficacy, 
tolerability, and safety of phlogenzym as compared to diclofenac in the treatment of 
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osteoarthritis. Inclusion criteria included osteoarthritis confirmed radiographically, a Lequesne’s 
Functional index >10, a WOMAC pain scale of >20. Exclusion criteria included patients less 
than 18 years of age, current or recent use of anti-rheumatic therapy within two weeks, pregnant 
or lactating women. A full report of demographics of the three final selections are reported and 
displayed in Table 1. The studies either reported p-values or contained dichotomous data, which 
could be used to calculate Relative Risk Reduction/Increase (RRR/RRI), Absolute Risk 
Reduction/Increase (ARR/ARI), and Number Needed to Treat/Harm (NNT/NNH). 
 Ahktar et al. selected 116 male and female patients with confirmed OA who met the 
inclusion and exclusion criteria were divided into two groups and assigned to two separate 
clinical centers in Pakistan.  After written consent was obtained, the participants were given the 
medication and dosing instructions, and compliance was monitor by pill counting at each visit.3 
 Klein et al. selected 90 patients who met the inclusion and exclusion criteria, and were 
randomized into separate groups at a specialized rheumatology center in Austria. After receiving 
written, informed consent, patients were provided the assigned medications and dosing 
instructions. Patient compliance was monitored by pill counting at the 3rd and 6th week visit.4  
 Tilwe et al. selected 50 patients who met the inclusion and exclusion criteria for an open 
randomized controlled trial. Patients were provided the assigned medications and dosing 
instructions after written, informed consent was obtained.5  
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Table 1: Demographics of included studies 
Study Type # 
pts 
Age Inclusion Criteria Exclusion Criteria W/D Intervention 
Akhtar3 
(2004) 
Double 
Blind RCT 
116 >18 yrs OA of one knee 
confirmed 
radiographically 
with a 
Lequesne’s 
Functional Index 
>10 
- Treatment within 2 weeks 
prior to the study for RA. 
- Disease causing 
secondary arthritis.  
- Patients who had systemic 
or intra-articular 
corticosteroid therapy 
20 Phlogenzym
(ERC) 
1 tablet TID  
Klein4 
(2006) 
Double 
Blind RCT 
90 >20 yrs 
Avg: 
51-53yrs 
- Men and 
women >20 years 
old, with hip OA 
lasting at least 3 
months and 
confirmed 
radiographically 
or CT.  
- A WOMAC 
pain scale of >20 
and a Lequesne’s 
pain and 
functional index 
between >10 and 
<14. 
 
- Arthritic or concurrent 
medical disease.  
- Abnormal lab results that 
had potential to interfere 
with evaluation.  
- Allergies or 
hypersensitivities to 
NSAIDS or an 
investigational drug.  
- Subject has received an 
investigational drug within 
30 days of study or 
received steroids or 
hyaluronic acid within 2 
months 
 
2 Phlogenzym  
2 tablets 
TID 
Tilwe5 
(2001) 
Randomized 
Controlled 
Clinical  
Trail (open) 
50 40-75 
yrs 
Avg:  
56-58 
Radiograph 
confirmation of 
arthroses 
- Current or use of anti-
rheumatic therapy within 2 
weeks 
- Arthroses secondary to 
systemic disease or 
bacterial infection of the 
joint.  
- Pregnant or lactating 
women. 
- Allergies or 
hypersensitivities to 
medicine components. 
- Steroid or anticoagulant 
therapy in the last 2 months 
 
0 Phlogenzym  
3 tablets 
BID 
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OUTCOMES 
The primary outcomes measured in all three studies were reports collected from 
participants regarding pain at rest and motion, and restricted function from baseline.  
For primary efficacy criteria, Akhtar et al. used Lequesne’s Algofunctional Index (LFI) 
and a complaint index, which was rated by using visual analog scales (VAS) ranging from 0 = 
best to 10 = worst, and reports were collected at baseline, 2 weeks, 4 weeks, and 6 weeks. Global 
efficacy, assessed by both participant and physician, was based on a 5-point scale ranging from 
1= very good to 5= poor. Patient and physician both reported a global judgment for safety and 
adverse events on a 5-point scale ranging from 1 = very good to 5 = poor.3 Kleine et al. also used 
Lequesne’s Algofunctional Index (LFI) and visual analog scales to assess primary efficacy at 
baseline, 3 weeks, and 6 weeks. Global judgment for safety was based on a 4-point categorical 
scale of 1 = bad to 4 = very good.4 Tilwe et al. evaluated participants for primary efficacy of 
pain, joint tenderness and swelling at baseline, week 3, and 4 weeks after completing therapy.  
Participants assessed pain at rest and with movement subjectively as: none, mild, moderate, 
severe; improvement was determined as any improvement from baseline results5. Joint 
tenderness was determined by physicians by applied pressure and reported as: none, slight, 
moderate, severe, very severe. Joint swelling was measured by physicians with a tape measure in 
centimeters, and range of motion was determined using a goniometer. Global judgment was 
assessed by participant and physician as poor, good, or very good.5  
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RESULTS 
 The results for two of the studies were reported as dichotomous data, and the continuous 
data in the Tilwe et al study was converted to dichotomous data.  
 Akhtar et al. reported the global judgment efficacy as receiving at least a minimum of 
“good” rating and was resulted as 51.4% and 37.2% in the phlogenzym and diclofenac groups 
respectively. The confidence interval was determined to be 97.5% for the groups and established 
p-value <0.05 demonstrating statistical significance during the time period. (Table 2) The 
adverse events that occurred between the groups were similar at 27.5% (14 patients) for 
phlogenzym and 23.1% (12 patients) for diclofenac, though majority were related to diarrhea, 
moderate severity adverse effects did result in five patients withdrawing from the phlogenzym 
group. One reported diarrhea, edema, and breathing complications; one reported epigastric 
burning; one reported dryness of mouth and loss of appetite; and one reported lumbosacral 
muscle spasms – all moderate severe adverse effects occurred within 2 weeks of starting the 
treatment. The relative risk increase (RRI) was calculated to be 19.0% and the absolute risk 
increase (ARI) was calculated to be 4.4%, these resulted in a numbers needed to harm (NNH) of 
23 patients when using the 1 tablet of phlogenzym three times a day (Table 3).  
 Klein et al. reported a global judgment efficacy at least of “good” or “very good” and was 
resulted as 62.8% for phlogenzym and 50.0% for diclofenac. Reports for LFI and complaint 
index were established at p=0.0025 demonstrating statistical significance during the time period 
(Table 2). Drug study adverse events that occurred were similar between the phlogenzym and 
diclofenac groups at 24.4% (11 patients) and 28.9% (13 patients) respectively, majority of the 
complaints regarded gastrointestinal disruption. Two severe adverse events occurred – one in 
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each group and were not contributed to the respective medication. The RRI was calculated to be 
15.6% and the ARI was calculated at 4.5%, these resulted in a NNH of 23 patients when using 
two tablets of phlogenzym three times a day (Table 3).  
 Tilwe et al. reported an average improvement from baseline of 34.5% and 20.9% for 
phlogenzym and diclofenac respectively. The data is statistically significant with p <0.05 
between the groups during the time period evaluated (Table 2). All participants were accounts 
for at the end of the study and no adverse events were reported; therefore, NNH could not be 
calculated (Table 3). 
Table 2 – Efficacy of Phlogenzym for Osteoarthritis 
Study Phlogenzym: 
Improvement of 
symptoms% 
Diclofenac: 
Improvement of 
symptoms% 
p-value RBI% ABI% NNT 
Akhtar, 
2004 
51.4 37.2 <0.05 19.0 4.4 8 
Klein, 
2006 
62.8 50.0 0.0025 25.6 12.8 8 
Tilwe, 
2001 
34.5 20.9 <0.05 19.0 16 7 
% = Values are reported in % from baseline 
  
Table 3 – Adverse effects that result in Numbers Needed to Harm 
Study Phlogenzym% 
 
Diclofenac% RRI% ARI% NNH 
Akhtar, 
2004 
27.5 23.1 19.0 4.4 23 
Klein, 
2006 
24.4                28.9 15.6 4.5  23 
Tilwe, 
2001 
0* 0* 0* 0*  0* 
% = Values are reported in % 
* = No adverse effects occurred per study 
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DISCUSSION 
 Osteoarthritis is a disease that commonly occurs in adults greater than 55 years.1 The 
disease is characterized by inflammation caused by progressive loss of cartilage and bony growth 
due to degeneration or trauma. The goal of treatment is to reduce symptoms, loss of function, 
and disease progression.1,2  
 Phlogenzym is a compounded medication that consists of three different enzymes: 
bromelain, rutin, and trypsin.3,4,5 This medication was designed to target the edema, 
inflammation, and healing process that occur with osteoarthritis. Bromelain is a plant protease 
that breaks down plasma proteins and decreases inflammation and edema of the interstitium.4,5 
Trypsin is an animal protease that helps to improve blood flow to the affected area by exerting a 
fibrinolytic action. Rutin is an antioxidative compound that eliminates radicals and stabilizes 
vascular endothelium and reduces intravascular space fluid.4,5  
 All three studies consisted of both male and female participants, and used visually 
matched tablets for both the experiment and controlled medications. Ahktar et al. was the only 
study that allowed participants to receive physical therapy during the trial period. Each of the 
studies lasted approximately six weeks, consisted of sample sizes of 120 participants or less, and 
it was reported that the blinding was not compromised in any of the studies.  
CONCLUSION 
 The studies reviewed demonstrated that phlogenzym does have an association with 
osteoarthritis pain reduction, but does not provide an adequate statistical difference between the 
intervention and control. Adverse events did occur during the study and mainly caused 
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gastrointestinal disturbances in the experimental group. Further investigation is warranted to 
determine if phlogenzym can improve OA disease. The studies only occurred over a six week 
period, thus lengthening the time period may provide more accurate data. Including physical 
therapy during the study period may improve the effectiveness of the drug. By evaluating 
participants at more frequent intervals may prove to offer a more tightly controlled study. Also, 
these studies used small populations of participants and did not compare the medication to a 
placebo. Thus, evaluating a larger population of patients over a longer time period, at more 
frequent intervals, while comparing the medication to a placebo may determine if phlogenzym is 
statistically significant in reducing moderate to severe osteoarthritis pain in adults. 
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